Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 3/20 | 0.39 |
| ▸ | CLK3 | P49761 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.38 |
| ▸ | CDK7 | P50613 | 6/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655332 | 0.85 | PIP5K1C (0.40) | PIP5K1CCHEK1CDK7HTTNPSR1 | |
| SCHEMBL13655325 | 0.85 | MC4R (0.40) | PIP5K1CCHEK1CDK7HTTNPSR1 | |
| SCHEMBL13655346 | 0.82 | CHEK1 (0.46) | CLK2CLK3DYRK1APIP5K1CCHEK1 | |
| SCHEMBL13655342 | 0.81 | TERT (0.41) | CLK2CLK3DYRK1APIP5K1CCHEK1 | |
| SCHEMBL13655331 | 0.80 | KDM4E (0.43) | PIP5K1CCHEK1CDK7SMN1; SMN2 | |
| SCHEMBL13655336 | 0.79 | CHEK1 (0.46) | PIP5K1CCHEK1CDK7 | |
| SCHEMBL13655345 | 0.78 | CLK2 (0.42) | CLK2CLK3DYRK1APIP5K1CCHEK1 | |
| SCHEMBL13655335 | 0.78 | PIP5K1C (0.44) | PIP5K1CCHEK1CDK7 | |
| SCHEMBL13655343 | 0.76 | CHEK1 (0.45) | PIP5K1CCHEK1CDK7 | |
| SCHEMBL13655326 | 0.74 | CHEK1 (0.60) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | CLK2 685/4885CLK3 1342/4885DYRK1A 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.